تقرير
Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES (O-MDS-Protocol)
| العنوان: | Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES (O-MDS-Protocol) |
|---|---|
| المساهمون: | Fortunato Morabito, MD |
| المصدر: | Abdel-Wahab O, Mullally A, Hedvat C, Garc-Manero G, Patel J, Wadleh M, Malge S, Yao J, Kpaara O, Bhat R, Huberman K, Thomas S, Dolgalev Heguy A, Patta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjn HM, Stone RM, Gland DG, Crpo JD, Leve RL. Genet characteratn of TET1, TET2, and TET3 alteratns myelo malnancs. Blood. 2009 Jul 2;114(1):144-7. do 10.1182/blood-2009-03-210039. Epub 2009 May 6. Bacher U, Haferlach C, Schntger S, Kohlmann A, Kern W, Haferlach T. Mutatns of the TET2 and CBL genes: novel molecular markers myelo malnancs. Ann Hematol. 2010 Jul;89(7):643-52. do 10.1007/s00277-010-0920-6. Epub 2010 Mar 2. Bennett JM, Catovsky D, Danl MT, Flandr G, Galton DA, Gralnk HR, Sultan C. Proposals for the classatn of the myelodysplast syndromes. Br J Haematol. 1982 Jun;51(2):189-99. Cazzola M, MalcovatL. Myelodysplast syndromes--copg wh effecte hematopos. N Engl J Med. 2005 Feb 10;352(6):536-8. do 10.1056/NEJMp048266. No abstract avaable. Couronne L, Lpert E, Andrux J, Kosmer O, Radford-Wes Penther D, Dastugue N, Mugneret F, Lafage M, Gachard N, Nadal N, Bernard OA, Nguyen-Khac F. Analyses of TET2 mutatns post-myeloprolerate neoplasm acute myelo leukems. Leukem. 2010 Jan;24(1):201-3. do 10.1038/leu.2009.169. Epub 2009 Aug 27. No abstract avaable. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, VallespT, Hambl T, Oscr D, OhyashK, Toyama K, Aul C, MuftG, Bennett J. ternatnal scorg system for evaluatg prognos myelodysplast syndromes. Blood. 1997 Mar 15;89(6):2079-88. Erratum : Blood 1998 Feb 1;91(3):1100. Harr NL, Jaffe ES, Dbold J, Flandr G, Muller-Hermelk HK, Vardan J, Lter TA, Bloomfld CD. The World Health Organatn classatn of neoplast deases of the hematopot and lympho tsues. Report of the Clal Advory Commtee meetg, Al House, Vg, November, 1997. Ann Oncol. 1999 Dec;10(12):1419-32. do 10.1023/a:1008375931236. Kosmer O, GelsBoyer V, Cheok M, Grabar S, Della-Valle V, Pard F, Vu F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardla P, Lacombe C, Vachenker W, Preudhomme C, Dreyfus F, Bernard OA, Bnbaum D, Fontenay M; Groupe Francophone des Myelodysplass. TET2 mutatn an dependent favorable prognost factor myelodysplast syndromes (MDSs). Blood. 2009 Oct 8;114(15):3285-91. do 10.1182/blood-2009-04-215814. Epub 2009 Aug 7. Langemeer SM, Kuer RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Lders E, van Hoogen P, van Kessel AG, Raymakers RA, Kampg EJ, Verhoef GE, Verburgh E, Hagemeer A, Vandenberghe P, de Wte T, van der Reden BA, Jansen JH. Acqued mutatns TET2 are common myelodysplast syndromes. Nat Genet. 2009 Jul;41(7):838-42. do 10.1038/ng.391. Epub 2009 May 31. Lorsbach RB, Moore J, Mathew S, RaondSC, Mukata ST, Downg JR. TET1, a member of a novel prote famy, fused to MLL acute myelo leukem contag the t(10;11)(q22;q23). Leukem. 2003 Mar;17(3):637-41. do 10.1038/sj.leu.2402834. No abstract avaable. Ma X, Does M, Raza A, Mayne ST. Myelodysplast syndromes: cence and surval the Uned States. Cancer. 2007 Apr 15;109(8):1536-42. do 10.1002/cncr.22570. MalcovatL, Ner SD. Myelodysplast syndromes: dgnos and stagg. Cancer Control. 2008 Oct;15 Suppl:4-13. do 10.1177/107327480801504s02. N HH, H.H., Jenks JG, Stemrenner K, Bent DH., SPSS (Stattal Package for the Socl Scnce). 1979, New York, NY: McGraw-Hl. Ono R, TakT, TaketanT, TanakM, KobayashH, HayashY. LCX, leukem-assocted prote wh a CXXC doma, fused to MLL acute myelo leukem wh treage dysplas havg t(10;11)(q22;q23). Cancer Res. 2002 Jul 15;62(14):4075-80. Rollon DE, Howlader N, Smh MT, Strom SS, Merrt WD, Rs LA, Edwards BK, Lt AF. Epemlogy of myelodysplast syndromes and chron myeloprolerate dorders the Uned States, 2001-2004, usg data from the NAACCR and SEER programs. Blood. 2008 Jul 1;112(1):45-52. do 10.1182/blood-2008-01-134858. Epub 2008 Apr 28. Sanz GF, Sanz MA, Greenberg PL. Prognost factors and scorg systems myelodysplast syndromes. Haematologa. 1998 Apr;83(4):358-68. Sekeres M, Cosgrove D, Falco A. Managg patnts wh low-rk MDS. Cl Adv Hematol Oncol. 2006 Jul;4(7 Suppl 16):1-10; qu 11-2. Swerdlow SH, Campo E, Harr NL, Jaffe ES, PerSA, Ste H et al, eds. WHO Classatn of Tumours of Haematopot and Lympho Tsues. RC: Lyon, 2008. TahnM, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, er LM, L DR, Aravd L, Rao A. Conversn of 5-methylcytose to 5-hydroxymethylcytose mammaln DNA by MLL partner TET1. Scnce. 2009 May 15;324(5929):930-5. do 10.1126/scnce.1170116. Epub 2009 Apr 16. TefferA, PardananA, L KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Fke CM, Schwager S, Mullally A, LCY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vachenker W, Gland DG, Leve RL. TET2 mutatns and the clal correlates polycythem vera, essentl thrombocythem and myelofros. Leukem. 2009 May;23(5):905-11. do 10.1038/leu.2009.47. Epub 2009 Mar 5. TefferA, L KH, Abdel-Wahab O, Lasho TL, Patel J, Patna MM, Hanson CA, PardananA, Gland DG, Leve RL. Detectn of mutant TET2 myelo malnancs other than myeloprolerate neoplasms: CMML, MDS, MDS/MPN and AML. Leukem. 2009 Jul;23(7):1343-5. do 10.1038/leu.2009.59. Epub 2009 Mar 19. No abstract avaable. Vardan JW, Harr NL, Brunng RD. The World Health Organatn (WHO) classatn of the myelo neoplasms. Blood. 2002 Oct 1;100(7):2292-302. do 10.1182/blood-2002-04-1199. Vu F, Aboura A, Bouscary D, Ramond S, Delmer A, Tachdjn G, Mar JP, Casadevall N. Common 4q24 deletn four cases of hematopot malnancy: early stem cell volvement? Leukem. 2005 Aug;19(8):1411-5. do 10.1038/sj.leu.2403818. Walker AH, Najarn D, Whe DL, Jaffe JF, Kanetsky PA, Rebbeck TR. Collectn of genom DNA by buccal swabs for polymerase cha reactn-based bmarker assays. Envon Health Perspect. 1999 Jul;107(7):517-20. do 10.1289/ehp.99107517. Woo JG, Sun G, Haverbusch M, dugula S, Mart LJ, Broderk JP, Deka R, Woo D. Qualy assessment of buccal versus blood genom DNA usg the Affymetr 500 K GeneCh. BMC Genet. 2007 Nov 8;8:79. do 10.1186/1471-2156-8-79. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, Kosmer O, Le Coued JP, Robert F, AlberdA, Lecluse Y, Plo Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulr J, Vu F, Fontenay M, Vachenker W, Bernard OA. Mutatn TET2 myelo cancers. N Engl J Med. 2009 May 28;360(22):2289-301. do 10.1056/NEJMoa0810069. Sat-Mart C, Leroy G, Delhommeau F, PanelattG, Dupont S, James C, Plo Bordessoule D, Chomnne C, Delannoy A, Devas A, Gardembas-Pa M, nard F, Plumelle Y, Bernard O, Vachenker W, Najman A, Bellanne-Chantelot C; French Group of Faml Myeloprolerate Dorders. Analys of the ten-eleven translocatn 2 (TET2) gene faml myeloprolerate neoplasms. Blood. 2009 Aug 20;114(8):1628-32. do 10.1182/blood-2009-01-197525. Epub 2009 Jun 29. Schm M. on chelatn therapy MDS: what have we learnt recently? Blood Rev. 2009 Dec;23 Suppl 1:S21-5. do 10.1016/S0268-960X(09)70006-2. Schouten JP, McElgunn CJ, Waaer R, Zwnenburg D, Dpvens F, Pals G. Relate quantatn of 40 nucle ac sequences by multlex latn-dependent probe amplatn. Nucle Acs Res. 2002 Jun 15;30(12):e57. do 10.1093/nar/gnf056. Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES |
| الوصول الحر: | https://clinicaltrials.gov/ct2/show/NCT01291745Test |
| قاعدة البيانات: | ClinicalTrials.gov |
| الوصف غير متاح. |